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A state of increased concentration of reactive
oxygen species (ROS) is a risk factor in a number of
diseases such as hypercholesterolemia, atheroscle-
rosis, hypertension, congestive heart failure,
diabetes, ischemia-reperfusion and neurodegene-
rative diseases, as well as acute and chronic
inflammatory diseases (1-3). The importance of
excessive ROS formation in these diseases can be
explained by the mechanism of action of excessive
oxidative stress: they cause damage of proteins,
lipids, and nucleic acids (4). Their role is also visible
in efficiency of different antioxidative compounds,
drugs, metabolites and vitamins for the maintenance
of an appropriate intracellular redox potential.
Ferric reducing ability of plasma (FRAP) is a
good index of total antioxidant capacity (TAC) of
plasma and it includes various enzymatic and non-
enzymatic antioxidant factors. Moreover, it is easy
to measure (5,6). In humans, the non-enzymatic
antioxidants contributing to FRAP are plasma uric
acid, bilirubin, α-tocopherol and L-ascorbic acid.
Plasma proteins and low molecular weight
compounds containing the SH group such as
glutathione (GSH) are of lower activity in FRAP
assay (5). The enzymatic factors of FRAP consist in
superoxide dismutase (SOD), glutathione peroxidase
(GPx), catalase (CAT) and GSH S-transferases
(GSTs) and they play an important role in
modulation of drug-induced oxidative damage. It is
commonly known that heritable deficiency of the
mentioned antioxidant enzymes favors ROS
accumulation, and has been associated with an
increased risk of vascular diseases. 
Many studies have shown the deleterious
effects of ROS on myocardium by both direct and
indirect measurements. Various antioxidants such as
SOD, CAT, GPx have been shown to prevent
myocardial ischemia-reperfusion injury. The seve-
rity of this injury, the subsequent level of oxidative
stress, and the interaction of antioxidants with ROS
determine the effectiveness of antioxidants for
cardioprotection. As an example, when ischemia-
reperfusion was found to increase H2O2, intracellular
calcium ([Ca2+]i), malondialdehyde (MDA) content
and the formation of conjugated dienes in the heart,
treatment of the heart with antioxidant enzymes
such as SOD plus CAT protected against these
changes (7).
Recently, direct evidence, using a genetically
engineered animal model, has been presented to
show the importance of CAT and SOD in not only
curing, but also protecting the myocardium against
ischemia-reperfusion injury (7). Although the acti-
vity of CAT in the myocardium has been reported to
be low, many studies have revealed its role of
protecting the heart from ischemia-reperfusion (8, 9).
Due to the presence of unpaired electrons in
outer orbitals, free radicals and ROS may contribute
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to damage of the antioxidant enzymes. CAT and
SOD play the key role in antioxidant defence in this
case. It has been reported that this enzyme system is
impaired in patients with cardiovascular diseases
such as hypertension or arrhythmia and that these
patients are exposed to oxidant stress (10, 11).
Despite numerous adverse side effects (e.g.
proatherosclerotic actions, peripheral circulatory and
respiratory disturbances, hypoglycaemia during diabe-
tic therapy), β-adrenoreceptor blocking agents (β-blo-
ckers) have been widely used in therapy, including
primary hypertension, angina pectoris, myocardial
infarction, heart failure and cardiac arrhythmias. 
In the last ten years a new generation of cardio-
selective (β1-selective adrenoreceptor) blockers, such
as metoprolol, atenolol or acebutolol, as well as non-
selective β-blockers with α-adrenoreceptor blocking
activity (e.g. carvedilol, bucindolol) were intro-
duced to therapy. In the case of carvedilol, beside its
β-blocking and antihypertensive function, anti-
oxidant activity in vitro and in vivo has been shown.
(12, 13) In the rat brain homogenates, carvedilol
protected α-tocopherol against depletion induced by
ferrous ions (14). Additionally, carvedilol decreased
oxidative stress in patients with heart failure and
hypertension (10). Antioxidant capacities of
clinically used antiarrhythmic agents e.g. mexile-
tine, amiodarone, propranolol and carvedilol, have
been established (10, 15-20).
This paper will focus on oxidative stress and




Epinephrine solutions, prepared for medical
use, were obtained from Polish Pharmaceutical
Corporation Polfa ñ Warsaw. Trolox and Resve-
ratrol were purchased from Sigma Aldrich. Other
chemicals were of analytical grade, purchased in
Industrial and Commercial Company ìPolish
Chemical Reagentsî (Poland).
The following 1-(phenoxyethyl)-piperazine
derivatives (Table 1) synthesized in the Department
of Technology and Biotechnology of Drugs








The physicochemical and hypotensive pro-
perties as well as affinities for adrenergic receptors
of the examined 1-(phenoxyethyl)-piperazine
derivatives 1-3 were described formerly (21).
Study samples
Venous blood samples K3EDTA, remaining
after diagnostic tests ordered in frames of routine
medical checking of big industrial enterprise
employers were used in the present study. Only
samples of clinically healthy subjects, 17 women
and 83 men, were included in the study. Every blood
sample was divided in two equal parts: the control
sample and the study sample. 0.9 mL blood in the
control sample was incubated with 0.1 mL
physiological solution of NaCl whereas 0.9 mL of
blood was incubated with 0.1 mL solution of given
compound in the indicated concentrations for 15
min, in 37OC (water bath). After incubation, one mL
of the whole blood was centrifuged at 1000 × g for
15 min at the room temperature. The plasma was
collected and retained for determination of the
FRAP. Red blood cells were washed 4 times with
physiological solution of NaCl, and lysed in 4.0 mL
of iceñcold double distilled water. In hemolysate
samples, SOD and CAT activities were measured as
described later.
The antioxidant profile of 1-(phenoxyethyl)-
piperazine derivatives [1-3] was compared to well
known antioxidants: Trolox and Resveratrol. All
study compounds and antioxidant standards were
investigated in concentration range from 10-8 to 10-4
mol × L-1(H2O).
Methods
TAC was assessed by method described by
Benzie et al. (5). The method used for the SOD
assay was first described by Misra and Fridovich
(9). This method is based on the SOD ability to
inhibit the epinephrine oxidation to adrenochrome.
The CAT activity was measured by Aebiís method
(21), which is a spectrophotometric method based
on the decline of hydrogen peroxide.
Statistical analysis 
Results were expressed as relative values.
TAC-FRAP in control plasma and antioxidant
enzymes activities in the control hemolysates were
taken as 100%. Antioxidant parameters of the
investigated samples were expressed as per cent of
the control samples. Differences between groups
were analyzed by Anova of Kruskal-Wallis, using
the STATISTICA for Windows PL software,
version 6.0 (Poland).
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RESULTS AND DISCUSSION
The starting point of the present study was the
statement, that some 1-(phenoxyethyl)-piperazine
derivatives [1-3] (Table 1), containing (2-methoxy)-
phenylpiperazine moiety, similarly to carvedilol, are
α1- and α2-blockers with additional β1-adreno-
receptor blocking activities (13). Compounds 1-3
inhibited ([3H] prazosin) binding with Ki from 84.6
to 244.5 nM and ([3H] clonidine) binding with Ki
from 252.3 to 410.8 nm to cortical α1- and α2- adre-
noreceptors, respectively. These compounds inhi-
bited moderately also (2-[3H]-CGP ñ 12177) binding
to β1-adrenoreceptors within µM range (Ki = 3.1 ñ
12.8 µM). The former studies in vivo showed that
examined compounds 1-3 possessed a significant
hypotensive activity in normotensive rats, but the
effect was weaker than that of carvedilol (22). 
On the other hand, the toxicity of studied compounds
was about half as low as that of the reference
compound (22). Due to the fact that ROS play an
important role in development of wide range of
cardiovascular diseases we decided to determine
antioxidant properties of appropriate 1-(pheno-
xyethyl)-4-[(2-methoxy)-phenyl]-piperazine derivatives
[1-3] (Table 1).
The results of this study are presented in
Figures 1-3 and they show that 1-(4-methyl)- and 1-
[(2,6-dimethyl)-phenoxyethyl]-piperazine derivati-
ves increased TAC of plasma samples as well as
SOD activity in red blood cells hemolysates. FRAP
values increased up to 160 ñ 195% of original values
in samples incubated with 1-[(4-methyl)-pheno-
xyethyl)-piperazine derivative [1] at concentrations
of 10-6 ñ 10-5 mol × L-1. This increase was similar to
that made by Trolox and greater than an increase
made by Resveratrol (p =0.05). 1-[(2,6-Dimethyl)-
phenoxyethyl)-piperazine [2], similarly to com-
pound 1, increased FRAP values from 109 to 206%.
The last 1-(phenoxyethyl)-piperazine derivative [3]
reduced ferric ions only at higher concentrations and
changed FRAP values as follows: enlarged FRAP
by about 36% and 16% at concentration of 10-5 and
10-6 mol × L-1 and decreased by about 67% and 82%
Figure 1. Effect of the studied compounds [1-3] on FRAP values in human plasma. * ñ difference between study and control samples by
U test of Mann-Whitney significant at p = 0,01; or ** ñ at p = 0,02; rectangulars represent values of medians; whiskers show 5 ñ 95 per-
centile values.
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Figure 2. Effect of the studied compounds [1-3] on the SOD activity in human red blood cells hemolysates. * ñ difference between study
and control samples by U test of Mann-Whitney significant at p = 0,01; or ** ñ at p = 0,02; rectangulars represent values of medians; whi-
skers show 5 ñ 95 percentile values.
Figure 3. Effect of the studied compounds [1-3] on the CAT activities in human red blood cells hemolysates. * ñ difference between stu-
dy and control samples by U test of Mann-Whitney significant at p = 0,01; or ** ñ at p = 0,02; rectangulars represent values of medians;
whiskers show 5 ñ 95 percentile values.
at 10-7 and 10-8 mol × L-1. The differences were
statistically significant (Figure 1). 
Superoxide dismutase (SOD) activity raised
markedly in red blood cells hemolysates after
incubation of samples with compound 1. This
compound enhanced SOD activity regardless of
concentration. The highest observed increase was
about 140% of original. Compounds 2 and 3 had
weaker effect on this enzyme activity. It was
observed that compound 2 caused an increase by
about 20 ñ 68% of the SOD activity. The highest rise
of this enzyme activity was noted at 10-7 mol × L-1.
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An addition of piperazine derivative with chlorine
[3], to blood samples, increased SOD activity by
about 40% at concentration range 10-7 ñ 10-5 mol ×
L-1 (Figure 2). 
All tested compounds decreased CAT activity.
The weaker and insignificant influence on CAT was
observed in case of compound 1. A decrease in CAT
activity to 70% of original was observed (Figure 3).
The first of standard antioxidants ñ Trolox ñ
increased statistically significantly every antioxi-
dant parameter at all used concentrations. It was
observed that this compound had the most effective
influence on CAT activity. At concentration of 10-5
mol × L-1, Trolox doubled CAT activity. Trolox had
also considerable, but weaker, effect on CAT
activity at concentration of 10-7-10-6 mol × L-1. The
discussed standard antioxidant effected SOD
activity regardless of concentration. There was ca.
20-30% increase of this enzyme activity. In samples
incubated with Trolox, FRAP values were larger
than in control samples by ca. 18-60% of the original
value. The greatest rise of TAC was observed in the
case of Trolox concentration of 10-5 mol × L-1.
The second antioxidant, Resveratrol had
statistically stronger antioxidant properties than
Trolox. Resveratrol was an efficient activator of
SOD. Doubled and tripled activity of this enzyme
was observed regardless of concentration. In the
case of second antioxidant enzyme, CAT, activity
increased proportionally to concentration of
Resveratrol from 128% at 10-8 mol × L-1, to 215% at
10-5 mol × L-1. Resveratrol also increased markedly
TAC of plasma, but weaker than antioxidant
enzymes.
The piperazine derivatives possessing 4-(me-
thyl)- or 1-[2,6-(dimethyl)-phenoxyethyl]-moiety
[1, 2] were significantly stronger than the reference
compounds at higher concentrations (10-5-10-6 mol ×
L-1). It was established that these compounds
increased TAC at every concentration. The decrease
of FRAP values seemed to be the result of the
introduction of the second methyl or chlorine
substituent in the phenyl ring.
Double substituted 1-(phenoxyethyl)-pipera-
zine moiety significantly caused activation of SOD
by compounds 2 and 3. 
1-(Phenoxyethyl)-piperazine analogues de-
creased CAT activity. The negative effect on CAT
activity was clearly weaker after incubation of red
blood cells with derivatives that had second methyl
group in the molecule. 
Summing up, 4-(methyl)- substituent in the
molecule of 1-(phenoxyethyl)-piperazine derivati-
ves seems to influence antioxidant properties of
these compounds. Two methyl groups caused the
increase of SOD activity, whereas single methyl
group increased TAC. An addition of chlorine atom
to appropriate (methyl)-phenoxyethyl moiety of 2-
(methoxyphenyl)-piperazine [3] may decrease antio-
xidant properties.
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